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Abstract
Background: Common oral diseases and dental caries can be prevented effectively by passive
immunization. In humans, passive immunotherapy may require the use of humanized or human
antibodies to prevent adverse immune responses against murine epitopes. Therefore we generated
human single chain and diabody antibody derivatives based on the binding characteristics of the
murine monoclonal antibody Guy's 13. The murine form of this antibody has been used successfully
to prevent Streptococcus mutans colonization and the development of dental caries in non-human
primates, and to prevent bacterial colonization in human clinical trials.
Results: The antibody derivatives were generated using a chain-shuffling approach based on human
antibody variable gene phage-display libraries. Like the parent antibody, these derivatives bound
specifically to SAI/II, the surface adhesin of the oral pathogen S. mutans.
Conclusions:  Humanization of murine antibodies can be easily achieved using phage display
libraries. The human antibody fragments bind the antigen as well as the causative agent of dental
caries. In addition the human diabody derivative is capable of aggregating S. mutans in vitro, making
it a useful candidate passive immunotherapeutic agent for oral diseases.
Background
Dental caries is one of the most common infectious dis-
eases of humans. The main causative agent is a group of
streptococcal species collectively described as the mutans
streptococci [1]. Streptococcus mutans has been identified
as the major etiological agent of the disease. Unlike many
other diseases, dental caries is as prevalent in the West as
it is in developing countries, and therefore attracts signifi-
cant interest from medical and dental authorities as well
as pharmaceutical companies. The first step in the initia-
tion of infection is the attachment of the bacterium to a
specific receptor, and this is an ideal point for interven-
tion. Two groups of proteins from mutans streptococci
represent primary candidates for a human caries vaccine:
i) glucosyltransferase enzymes, which synthesize adhesive
glycans and allow microbial accumulation, and ii) cell
surface fibrillar proteins that mediate adherence to the sal-
ivary pellicle [2]. The bacterial adhesin SAI/II [3], a
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surface-displayed protein with a molecular mass of 190
kDa, plays an important role in the initial attachment of
S. mutans to the tooth surface. Antibodies recognizing this
protein prevent colonization of the buccal cavity by the
bacterium and could be developed as a vaccine against
dental caries. The most suitable vaccination strategy
would be passive immunization, in which monoclonal
antibodies or fragments thereof are applied to the tooth
surface e.g. using toothpaste, mouthwash or chewing
gum. This would make active immunization with the S.
mutans adhesin unnecessary.
The murine monoclonal antibody Guy's 13 [4] which spe-
cifically recognizes the SAI/II protein of S. mutans and
Streptococcus sobrinus has been used successfully to prevent
S. mutans colonization and the development of dental car-
ies in non-human primates [5]. The antibody also pre-
vented bacterial colonization in human clinical trials
[6,7]. However, like other murine antibodies, a major lim-
itation in clinical applications may be the human anti-
mouse antibody response (HAMA), which can increase
the rate of clearance and initiate allergic reactions [8]. The
problems associated with murine antibodies can be over-
come by replacing murine sequences with their human
counterparts, e.g. by chimerization [9], CDR grafting [10]
and guided selection using phage display technology [11].
Furthermore, the use of antibody fragments rather than
whole antibodies also removes some of the constant
regions that may provoke an immune response.
There has been a growing interest in the use of single-
chain fragment variable (scFv) antibodies, in which the
variable regions of the heavy and light chains are com-
bined in the same polypeptide chain (Huston, 1988
#2785). The advantages of such derivatives are that they
can be expressed as single transgenes in various hosts, they
fold spontaneously to adopt the correct tertiary structure,
and their small size facilitates tissue penetration. The scFv
has the heavy and light chain variable regions joined by a
flexible peptide linker allowing the two domains to inter-
act, forming a univalent antibody. Alternatively, diabod-
ies have the same structure but the two domains are
joined by a shorter, less-flexible linker, forcing dimeriza-
tion and the formation of divalent antibodies (Holliger,
1993 #3498).
We have generated human derivatives of the murine Guy's
13 antibody using a chain-shuffling approach based on
human antibody variable gene phage-display libraries.
We have taken the variable gene regions of the original
Guy's 13 monoclonal antibody and created human scFv
and diabody derivatives by chain shuffling in human
phage-display libraries. Firstly, the heavy chain variable
gene of the Guy's 13 construct was introduced into a naïve
human light chain phage display library to select human
light chains that, in combination with the murine heavy
chain, showed binding specificity for the SAI/II antigen.
Once such chimeric antibodies had been selected, the
murine heavy chain gene was replaced with the human
counterpart, by introducing the selected human light
chain genes into a human heavy chain phage display
library.
The resulting clones were expressed in bacteria and tested
for specificity in ELISAs using both SAI/II antigen and
whole S. mutans. The stepwise procedure for generating
human antibody chains allows the advantages of scFv and
diabody antibody fragments to be exploited without suf-
fering the negative effects of non-human antibodies in a
clinical setting. The human antibody fragments were
expressed in bacteria as scFv and diabody derivatives and
used to aggregate S. mutans in vitro. The diabodies were
able to aggregate the bacteria and therefore have the
potential to be developed as therapeutic agents to treat
and/or prevent dental caries.
Results
Human recombinant scFv antibodies against SAI/II
Human scFv antibody fragments based on the murine
monoclonal antibody Guy's 13 were constructed using
two consecutive rounds of variable-domain shuffling and
phage-library selection (Figure 1). First, a chimeric scFv
was generated by amplifying the murine Guy's 13 heavy
chain variable region, and inserting it into a human light
chain variable region phage display library. The resulting
phage display library had a complexity of 5 × 105. Single
chain Fv antibody fragments with appropriate binding
activities were selected on purified, immobilized SAI/II
antigen. Three rounds of selection were carried out and
unique candidate antibodies were identified by ELISA
(Figure 2). Subsequent sequencing yielded five antibody
fragments (chimscFvA1, chimscFvA6, chimscFvA9,
chimscFvB4, and chimscFvG4). Sequencing of the human
variable genes showed that two of the clones chimscFvA6,
chimscFvB4 belonged to family Vκ1, clone chimscFvA6
was homologous to HK137 and chimscFvB4 was homol-
ogous to the L12 germline gene family. ChimscFvA9
belonged to family Vκ4 DPκ24. ChimscFvA1 and
chimscFvG4 belonged to family Vλ3 DPL16) (data not
shown). Inhibition ELISA showed that the binding of all
six chimeric scFvs to SAI/II could be inhibited by the
murine monoclonal antibody Guy's 13. The binding of
chimeric scFvs A6, A9, B4 and C6 was inhibited by
approximately 80%, suggesting that epitope recognition
was maintained (Figure 3). The binding of the chimeric
scFvs A1 and G4 was only inhibited by approximately
30%, suggesting that these antibodies recognized a differ-
ent epitope.BMC Biotechnology 2005, 5:4 http://www.biomedcentral.com/1472-6750/5/4
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Construction and selection of human SAI/II specific antibody fragments Figure 1
Construction and selection of human SAI/II specific antibody fragments. A: Antibody formats: scFv, in which the variable 
regions of the antibody heavy and light chains are combined in the same polypeptide chain joined by a (Gly4Ser)3 amino acid 
linker. The diabody construct consists of the antibody variable heavy and light chain domains linked by a ten-amino-acid linker 
(TGGGGSSSAL), forcing the expressed domains to attach to a complementary chain in solution to create two antigen-binding 
sites. scFv presentation as a protein3 fusion of the M13 phage. B: Chain shuffling approach: The variable antibody domain is 
cloned into a phagemid vector containing a human antibody variable domain library. The selection on SAI/II antigen was carried 
out for three consecutive rounds. Light chains participating in binding to SAI/II were identified and cloned into a phagemid vec-
tor containing a human antibody heavy domain library. Selection on SAI/II antigen for three rounds yielded fully human SAI/II 
specific scFv antibody fragments.
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Specificity of chimeric scFv (mGuy13VH/huVL) Figure 2
Specificity of chimeric scFv (mGuy13VH/huVL) ELISA reactivity of overnight induced bacterial culture supernatant containing 
chimeric scFv (mGuy13VH/huVL) after 3 rounds of selection on SAI/II antigen. A: 96 individual scFvs on SAI/II coated ELISA 
plates. B: the same 96 scFvs on BSA coated ELISA plates
Table 1: Deduced amino acid sequence of the heavy and light chain variable regions of human scFv and diabody.
scFv FR1 CDR1 FR2 CDR2
MuVHGuy13 QVKLQESGPDLVKPGASVKISCKASGYTFT DYNIH WVKQSRGKSLEWIG YIYPYNGNTYYNQKFKN
MuVLGuy13 DIELTQSPAIMSASPGEKVTITC SASSSVSYMH WFQQKPGTSPKLWLY STSNLAS
HuVHB10 QVQLQESGAEVKKPGLGEGLLQASGGTFS RYALS WVRQAPGQGLEWMG GIIPIFGTTNYAQKFQG
HuVLB10 DIQMTQSPSSLSASVGDRVTITC RASQGISNYLA WFQQKPGKAPKSLIY AASSLQS
HuVHD12 QVQLQEXGAEVKKPGESLKIXCKGSGYSFT SYWIG WVRQMPGKGLEWMG IIYPGDXDTRYSPSFQG
HuVLD12 DIQMTQSPSTLSASIGDRVTITC RASEGIYHWLA WYQQKPGKAPKLLIY EASRLQS
HuVHH6 QVQLQESGGGVVQPGRSLRLSCAASGFTFS SYAMH WVRQAPGKGLEWVS YISSSGSYIYYADSVKG
HuVLH6 DIVMTQSPSSLSASVGDRVTITC RASQGISNYLA WFQQKPGKAPKSLIY AASSLQS
scFv FR3 CDR3 FR4
MuVHGuy13 KATLTVDNSSTSAYMELRSLTSEDSAVYYCAT YFDY WGQGTTVTVS
MuVLGuy13 GVPARFSGSGSGTSYSLTISRMEAEDAATYYC HQRTSYPYT FGGTKLEIKR
HuVHB10 RVTIAADESTSTAYLELSSLRSEDTALYYCAK SYDYVWGSYRPNEYGLDI WGQGTMVTVS
HuVLB10 GVPSKFSGSGSGTEFTLTISSLQPEDFATYYC QELISYPLT FGGGTKLEIKRA
HuVHD12 QVTISADKSISTAYLQWSSLKASDTAMYYCA
R
LGLQDDYVWGSXNWFDP WGQGTLVTVSTS
HuVLD12 GVPSRFSGSGSGTEFTLTISSLQPDDFATYYC LQDFTYPRT FGQGTKVEIKRA
HuVHH6 RFTISRDNAKNSLYLQMNRLRAEDTAVYYC
AR
DMAGTSYYYYYMDV WGKGTLVTVSTS
HuVLH6 GVPSKFSGSXSGTEFTLTISSLQPEDFATYYC QELISYPLT FGGGTKLEIKRA
FR = antibody framework region, CDR = complementarity determining regionBMC Biotechnology 2005, 5:4 http://www.biomedcentral.com/1472-6750/5/4
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The selected human VL  genes were introduced into a
human VH library (complexity 8 × 108) and a combinato-
rial library with a complexity of 1 × 106 was established.
Three rounds of selection were carried out in solution
using SAI/II antigen coupled to paramagnetic beads.
Eleven human scFvs were identified by ELISA (data not
shown). Subsequent sequence analysis identified three
human scFvs: clones huscFv B10, huscFv D12 and huscFv
H6. Table 1 shows the amino acid sequences of the
human scFv antibody fragments. The human VL domain
in chimeric scFv A6 (Vκ1 HK137) was selected in combi-
nation with two different human variable heavy chains,
giving human scFvs B10 and H6, respectively. The VH
domain of human scFv B10 is homologous to VH1 family
DP10, and the VH domain of human scFv H6 is homolo-
gous to VH3 family DP35. The human VL domain in chi-
meric scFv B4 (Vκ1 L12) was selected in combination with
one human variable heavy chain giving the human scFv
D12. The VH domain of human scFv D12 is homologous
to VH5 family DP73. Figure 4 shows the binding of the
three human scFvs to the SAI/II antigen and the patho-
genic bacterium S. mutans. Inhibition ELISA showed that
Inhibition of chimeric scFv (mGuy13VH/huVL) to SAI/II by the monoclonal Ab Guy13 Figure 3
Inhibition of chimeric scFv (mGuy13VH/huVL) to SAI/II by the monoclonal Ab Guy13. Chimeric scFv were allowed to bind to 
SAI/II followed by replacement with an access of mAb Guy 13. The experiments were carried out in duplicate and the mean 
values are shown. Bound scFv were detected via their MYC-tag. The murine mAb Guy13 bound to the SAI/II. The scFv Guy13 
was not replaced by an unrelated mAb (ctrl.) Binding of A1 and G4 was only inhibited by 36% and 25%, respectively indicating 
that these scFv might recognize a different epitope than mAb Guy13. The binding of chimeric scFv A6, A9, B4, and C6 were 
inhibited between 77–84% indicating that they recognize the same epitope as mAb Guy13.BMC Biotechnology 2005, 5:4 http://www.biomedcentral.com/1472-6750/5/4
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the binding of all three human scFvs to SAI/II was inhib-
ited by Guy's 13, suggesting that epitope recognition was
maintained.
Generation of human diabodies and agglutination of S. 
mutans
Recombinant antibody fragments can be engineered to
assemble into stable multimeric oligomers of high bind-
ing avidity and specificity [12]. A scFv molecule joined by
a linker of 3–12 residues cannot fold into a functional Fv
domain and instead associates with a second scFv mole-
cule to form a bivalent dimer (diabody, approx. 60 kDa).
For the cross-linking of cell surface antigens, at least two
binding domains are necessary. The diabody is the small-
est bivalent antibody molecule that can fulfill this prereq-
uisite. Through reduced off-rates, which result from
multiple binding to two target antigens and to rebinding
when one Fv dissociates, the diabody is suitable to facili-
tate specific agglutination of bacteria. We constructed
human diabodies by isolating the variable heavy and light
chain genes from human scFvs B10, D12 and H6 and
murine scFv Guy's 13, amplified by PCR (Table 2) and
inserting them in two consecutive steps into the vector
pHenIXdia, containing a 10 amino acid residue linker.
The integrity of the clones was confirmed by sequencing
and the binding activity was demonstrated by ELISA using
Binding of human diabodies to SAI/II and S. mutans coated ELISA plates Figure 4
Binding of human diabodies to SAI/II and S. mutans coated ELISA plates. One µg SAI/II or 10 ml S. mutans culture were immobi-
lized on the ELISA plate. Binding of 1 µg human diabody B10, D12 and H6 was detected via the His6tag. The experiments were 
carried out in duplicate and the mean values are shown. The three human diabodies recognize the SAI/II antigen in the purified 
form as well as in the context of the bacterial surface.BMC Biotechnology 2005, 5:4 http://www.biomedcentral.com/1472-6750/5/4
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both the SAI/II antigen and S. mutans cells (Figure 4). Ma
et al. [7] reported that bivalent binding of the murine
Guy's 13 is required for protection against dental caries,
since the F(ab')2 derivative was protective but not the
monovalent Fab fragment. S. mutans was aggregated in a
dose dependent manner when grown in the presence of
murine diabody Guy's 13 and human diabody D12 (Fig-
ure 5A and 5B).
Discussion
Antibodies recognizing and neutralizing the oral patho-
gen S. mutans provide a novel approach for the control
and prevention of dental caries. A monoclonal antibody
that binds specifically to the SAI/II surface adhesin of S.
mutans was isolated by Smith et al. (20) and has been
expressed in plants as a secretory IgA (sIgA) [13]. In
ongoing Phase II clinical trials, this recombinant antibody
has been shown to prevent recolonization of the mouth
by S. mutans when coated onto the teeth and gums follow-
ing eradication of the bacteria. The sIgA is probably the
most appropriate format for the topical application of
antibodies that inhibit the colonization of the tooth sur-
face by S. mutans because this is the predominant form of
antibody naturally found in the saliva. However, each
sIgA comprises ten polypeptide chains of four different
types making it difficult to produce on a large scale in con-
ventional production systems. The more convenient dia-
body antibody derivatives, which can be expressed in
large quantities in microbial culture systems, may be more
suitable for the type of production scales that would be
required for the routine control of dental caries using this
strategy.
As a first step in this direction, we have taken the variable
gene regions of the original Guy's 13 monoclonal anti-
body and created human scFv and diabody derivatives by
chain shuffling in human phage-display libraries. The
heavy chain variable gene of the Guy's 13 construct was
introduced into a naïve human light chain phage display
library to select human light chains that, in combination
with the murine heavy chain, showed binding specificity
for the SAI/II antigen. Once such chimeric antibodies had
been selected, the murine heavy chain gene was replaced
with the human counterpart, by introducing the selected
human light chain genes into a human heavy chain phage
display library.
The resulting clones were expressed in bacteria and tested
for specificity in ELISAs using both SAI/II antigen and
whole S. mutans. The stepwise procedure for generating
human antibody chains allows the advantages of scFv and
diabody antibody fragments to be exploited without suf-
fering the negative effects of non-human antibodies in a
clinical setting. Small scFv and diabody antibody frag-
ments are easy to express in large quantities, they pene-
trate tissues easily and they lack the constant domains that
promote often-unwanted and usually superfluous effector
functions. However, where such antibodies are murine in
origin, they can provoke an immune reaction in the
human host, leading to rapid clearance and poor efficacy
during long-term treatment. Since dental caries tends to
be chronic rather than acute, murine antibodies would be
of little benefit to patients in the long term.
Two drawbacks of scFvs compared to the ideal sIgA format
are monovalency and instability. ScFvs are monovalent
because the heavy and light chains are joined by a flexible
peptide linker, which allows the two domains to fold and
interact with each other. We have addressed this problem
by converting the scFv antibodies into diabodies, which is
achieved by shortening the linking peptide and forcing
the heavy and light chain variable domains to seek inter-
action partners as part of a dimer. As a consequence of this
interaction, the diabody is bivalent like the parent immu-
Table 2: Construction of human diabodies. Primer combinations and primer sequences
Template VL amplification VH amplification
pHenIX human scFv B10 Vκ1 ApaL1 Jκ1 Not1 VH4 Sfi1/Nco1 JH3 for Sal1
pHenIX human scFv H6 Vκ1 ApaL1 Jκ1 Not1 VH6 Sfi1/Nco1 JH2 for Sal1
pHenIX human scFv D12 Vκ1 ApaL1 Jκ1 Not1 VH4 Sfi1/Nco1 JH2 for Sal1
pHenIX scFv mGuy13 mGuy13 ApaL1 mGuy13 Not1 VH4 Sfi1/Nco1 mGuy13 Sal1
Vκ1 ApaLI: 5'-TGAGCACACAGTGCACTCGACATCCAGATGACCCAGTCTCC-3'
Jκ1 Not1: 5'-GAGTCATTCTCGACTTGCGGCCGCACGTTTGATC/TTCCAC/GCTTGGTCCC-3'
VH4 Sfi1/Nco1: 5'-GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCCAGGTGCAGCTGCA/ GGAGTCGGG-3'
VH6 Sfi1/Nco1: 5'-GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCCAGGTACAGCTGCA/ GCAGTCAGG-3'
JH3 Sal1: 5'-GAGTCATTCTCGTGTCGACACGGTGACCATTGTCCC-3'
JH2 Sal1: 5'-GAGTCATTCTCGTGTCGACACAGTGACCAGGGTGCC-3'
mGuy13 ApaL1I:5'-TGAGCACACAGTGCACTCGACATCGAGCTCACTCAGTCTCC-3'
mGuy13 Not1: 5'-TTTTCCTTTTGCGGCCGCCCGTTTTATTTCCAACTTTGT-3'
mGuy13 Sal1: 5'-GAGTCATTCTCGTGTCGACACGGTGACCGTGGTGCCTTGGCCCCAGTAGTCAAAGTAGGT-3'BMC Biotechnology 2005, 5:4 http://www.biomedcentral.com/1472-6750/5/4
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Bacterial agglutination assay Figure 5
Bacterial agglutination assay. S. mutans was incubated with serial dilutions of diabody for 1 h at 37°C followed by counterstain-
ing with Gram solution and analysis by microscopy. A: Murine diabody mGuy13. B: Human diabody D12. Neg. ctrl.: Unrelated 
human diabodyBMC Biotechnology 2005, 5:4 http://www.biomedcentral.com/1472-6750/5/4
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noglobulin, and therefore has increased binding avidity.
We showed that the bivalent binding of the diabody anti-
body constructs leads to agglutination of S. mutans.
The problem of decreased stability may be more difficult
to address, because the efficacy of scFv and diabody mol-
ecules used to treat dental caries will depend largely on
their persistence and effective concentration. Secretory
IgAs include a secretory component, which protects the
antibody from proteolytic degradation in the saliva. One
possible solution is to include this secretory component
in any scFv or diabody format through the use of further
gene fusion strategies. However, it is envisaged that
antibodies for the prevention of dental caries will be
administered in the form of toothpaste or mouthwash, or
perhaps chewing gum, which will allow the treatment to
be refreshed at regular intervals.
Conclusions
We have shown that the humanization of a murine mon-
oclonal antibody can be easily achieved using a chain-
shuffling approach based on scFv antibody phage display
libraries. The human antibody derivatives of the murine
Guy's 13 antibody can be expressed and isolated from
bacteria, recognize SAI/II and S. mutans with great specifi-
city, and can successfully aggregate S. mutans cells in the
dimeric form in a dose dependent manor. These recom-
binant therapeutic proteins therefore represent the first
step towards an inexpensive and convenient general treat-
ment for dental caries.
Methods
Propagation of S. mutans
S. mutans 20523 serological group c was purchased from
DSMZ (Braunschweig, Germany) and grown in an S2
containment laboratory in trypticase soy yeast extract
medium (30 g l-1 trypticase soy broth, 3 g l-1 yeast extract,
pH 7.0–7.2) at 37°C for 2 d prior to use.
Cloning the S. mutans spaP gene encoding surface antigen 
SAI/II
Nucleotides 214–3048 of the spaP gene [14], which
encodes the SAI/II antigen, were removed from pUC18 as
a SfiI/NotI fragment and inserted into the bacterial expres-
sion vectors pCantab5E (Pharmacia) and pSin1 [15]
which had been digested with the same enzymes followed
by transformation into E. coli TG1. The pCantab5E vector
contained an additional sequence encoding the E-tag,
facilitating the detection of expressed proteins using the
monoclonal antibody 5E (Pharmacia). The pSin1 vector
similarly contained sequences encoding a MYC-tag, facili-
tating detection with the murine monoclonal antibody
9E10 (ATCC CRL 1729), and a His6 tag, allowing purifica-
tion of expressed proteins by immobilized metal-chelate
affinity chromatography (IMAC) and detection using a
murine Penta-HIS antibody (Qiagen). SAI/II expressed
using pSin1 was used for the selection of antibodies from
phage-display libraries. SAI/II expressed in pCantab5E
was used for enzyme-linked immunosorbent assays
(ELISAs).
Coating paramagnetic beads with SAI/II
For the selection of phage-display antibodies, 250 µl of
phosphate-buffered saline (PBS)-washed Dynabeads
(Dynal Biotech GmbH) was resuspended in 500 µl 0.1 M
phosphate buffer (pH 7.4) and mixed gently for 2 min.
The beads were collected with a magnet, the supernatant
discarded and the beads resuspended in 250 µl of the
same buffer, followed by the addition of 500 µl SAI/II
antigen (1 mg/ml). After incubation for 16 h at 37°C with
slow tilt rotation, the beads were collected with a magnet
and the supernatant was discarded. The coated beads were
washed four times, twice with 0.13 M NaCl, 1% milk
powder in 0.01 M phosphate buffer (pH 7.4) for 5 min at
4°C, once with 0.2 M Tris-HCl (pH 8.5) for 4 h at 37°C
and again in the same buffer for 5 min at 4°C.
Cloning scFv Guy's 13 in pSin1
The variable region genes of the heavy and light chain of
the murine monoclonal antibody Guy's 13 were ampli-
fied using oligonucleotide primers LMB3 (5' CAG GAA
ACA GCT ATG AC 3') and fdSeq 1 (5' GAA TTT TCT GTA
TG/AG GG 3') followed by digestion with SfiI and NotI.
The products were inserted into the phagemid vector
pSin1, which had been treated with the same enzymes,
and the recombinant vector was introduced into E. coli
strain TG1.
Construction and selection of human SAI/II-specific scFv 
antibodies
Figure 1 shows the schematic scheme of the construction
and selection of human SAI/II specific scFv antibody
approach. The variable heavy chain antibody domain of
the murine antibody Guy's 13 was cloned as an SfiI/SalI
fragment in the bacterial expression vector pHenIX con-
taining a light-chain antibody phage-display library
derived from naïve human peripheral blood lymphocytes
(8 × 108; R. Finnern, unpublished data). This vector is
based on the phagemid vector pHen1 [16] designed to
express antibody fragments as N-terminal fusions with the
minor coat protein of filamentous bacteriophage M13. An
amber stop codon between the two fusion partners allows
the expression of both soluble antibody fragments and
phage particles displaying recombinant antibodies. The
recombinant vectors were introduced into E. coli strain
TG1.
Three rounds of selection were carried out using immobi-
lized SAI/II antigen as described by Marks et al. [17]. Elu-
tion was achieved using the monoclonal antibody Guy'sBMC Biotechnology 2005, 5:4 http://www.biomedcentral.com/1472-6750/5/4
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13 to select binders recognizing the same epitope. The
expression of soluble scFvs was performed as described by
Marks et al. [17] and scFvs specific for the SAI/II antigen
were identified by ELISA using SAI/II antigen.
The selected variable antibody domain genes of the shuf-
fled human light chains were cloned as ApaLI and NotI
fragments in pHenIX containing a human variable heavy
chain library (8 × 108; R. Finnern, unpublished data) and
introduced into E. coli TG1. This was achieved by PCR
amplification of the human light chain genes using prim-
ers Vκ4  ApaLI (5'-TGAGCACACAGTGCACTCGA-
CATCGTGATGACCCAGTCTCC-3'), Vκ1  ApaLI (5'-
TGAGCACACAGTGCACTCGACATCCAGATGAC-
CCAGTCTCC-3') and Jκ1  NotI (5'-GAGTCATTCTC-
GACTTGCGGCCGCACGTTTGATC/TTCCAC/
GCTTGGTCCC-3').
Three rounds of selection were carried out using SAI/II
antigen immobilized on Dynabeads. Briefly, 150 µg of
SAI/II-coated beads was blocked for 1 h with 2 ml 2%
milk powder. The beads were collected with a magnet,
washed in PBS and incubated with the antibody phage
display library for 1 h on a turntable. The beads were
washed 15 times with PBS containing 0.05% Tween 20
and 15 times with PBS to remove unbound phage. Bound
phage were eluted with 100 µl 100 mM triethanolamine
for 10 min on a turntable followed by neutralization in
200 µl 1 M Tris-HCl (pH 8.0). Eluted phage were used to
infect exponentially growing E. coli TG1 and grown over-
night at 30°C on TYE plates containing 100 µg ml-1 amp-
icillin, 1% glucose. Selection, phage rescue and induction
of soluble scFv expression were carried out as described by
Marks et al. [17]. Antigen-specific human scFvs were iden-
tified by ELISA using the SAI/II antigen.
Propagation of phage display antibody libraries
One litre of 2× TY (supplemented with 100 µg ml-1 ampi-
cillin, 1% glucose) was inoculated with an aliquot of the
phage antibody library glycerol stock. The rescue and
induction of the phage was carried out essentially as
described in Marks et al. [17]. Phagemid rescue was car-
ried out by the addition of 1010 units of helper phage
VCSM13 (Pharmacia) to the growing phage antibody
library. The culture medium was changed to 2× TY con-
taining 100 µg ml-1 ampicillin and 25 µg ml-1 kanamycin
and incubated on an orbital shaker overnight at 30°C and
250 rpm. Phage were purified twice by polyethylene gly-
col (PEG) precipitation (20% PEG, 2.5 M NaCl) and
resuspended in a final volume of 2 ml PBS. The phage
were stored at 4°C until further use.
DNA sequencing
The number of unique clones was determined by PCR
amplification of the recombinant antibody inserts using
primers LMB3 (5' CAG GAA ACA GCT ATG AC 3') and
fdSeq 1 (5' GAA TTT TCT GTA TG/AG GG 3') followed by
digestion with the restriction enzyme BstNI (New England
Biolabs). The variable antibody genes from two clones of
each restriction pattern were analyzed by PCR cycle
sequencing using infrared-labeled primers according to
the manufacturer's instructions (Licor). Sequencing reac-
tions were carried out on a Licor automated DNA
sequencer (4000 L) and the sequences were analyzed
using Sequencher 3.1 (Gene Codes Corporation). The
sequences of the VH and VL genes were compared with the
germline sequences in the V-BASE database (Tomlinson et
al., MRC Centre for Protein Engineering, Cambridge, UK).
Construction of diabodies
The construction of diabodies [18] was carried out by PCR
amplification of the variable heavy and light chain
antibody regions of the human scFv clones and subclon-
ing these in vector pHenIXdia. The diabody constructs
consisted of the variable heavy and light chain antibody
domains linked by a ten-amino-acid linker (TGGGGSS-
SAL), forcing the expressed domains to attach to a com-
plementary chain in solution to create two antigen-
binding sites. The primers used for the construction of the
diabody antibody format are listed in Table 1.
Upscaled production of recombinant proteins
Recombinant proteins were recovered from the bacterial
periplasm following induction with 0.5 mM final concen-
tration of isopropyl-β-D-galactopyranoside (IPTG) for 3–
4 h at 30°C [19]. After centrifugation (4000 × g, 4°C, 30
min), the pellet was resuspended in 10 ml 30 mM Tris-
HCl (pH 8.2) containing 20% sucrose, 1 mM ethylenedi-
aminetretaacetic acid (EDTA), incubated on ice for 15 min
and centrifuged as above. The pellet was resuspended in
10 ml 5 mM MgSO4, 1 mM EDTA and incubated for 15
minutes on ice before a final centrifugation step as above.
Both supernatants were pooled, dialyzed against PBS and
stored at 4°C.
Recombinant proteins were also expressed in the peri-
plasm under osmotic stress in the presence of compatible
solutes as described by Barth et al. [20]. Briefly, bacteria
were grown overnight at 26°C in Terrific Broth (TB) (12 g
l-1 bacto-tryptone, 24 g l-1 bacto-yeast-extract, 4 ml l-1 glyc-
erol) containing 100 µg ml-1  ampicillin and 0.5 mM
ZnCl2. The culture was diluted 30-fold in 200 ml of the
same medium. When the OD600 nm of the culture reached
2.0, it was supplemented with 0.5 M sorbitol, 4% NaCl,
40 mM glycine betaine and incubated at 26°C for an addi-
tional 30–60 min. Expression was induced with 1 mM
final concentration IPTG and growth for 6 h at 26°C. Cells
were harvested by centrifugation at 30,000 × g for 10 min.
The recombinant antibody fragments were isolated from
the periplasmic space as described above. The periplasmicBMC Biotechnology 2005, 5:4 http://www.biomedcentral.com/1472-6750/5/4
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and osmotic shock fractions were pooled and dialyzed
against PBS. Phenylmethylsulfonylfluoride (PMSF) was
added to a final concentration of 1 mM.
Purification of recombinant proteins
The human scFv and diabody antibody fragments were
purified by IMAC using the His6 tag as described by Grif-
fiths et al. [21]. Briefly, 10 ml columns (BioRad Polyprep
chromatography columns) were packed with 500 µl Ni-
NTA resin (Qiagen) and washed with five column vol-
umes of PBS prior to loading with the recombinant
proteins. The columns were washed with 10 column vol-
umes of PBS containing 10 mM imidazol. Bound proteins
were eluted with 250 mM imidazol and collected in 1-ml
fractions. Protein concentrations were determined by
spectrophotometry assuming that A280 nm = 1 corresponds
to a scFv or diabody concentration of 0.7 mg ml-1.
Gel filtration was used for further purification. A Sepha-
dex 200 column (Pharmacia) was equilibrated with PBS.
ScFv or diabody antibody fragments were loaded and run
at 1 ml min-1. Aprotinin (6500 Da), cytochrome C
(12,400 Da), carbonic anhydrase (29,000 Da), bovine
serum albumin (BSA) (66,000 Da) and Dextran Blue
(2,000,000 Da) were used as molecular weight standards
(Fluka).
Enzyme linked immunosorbent assay (ELISA)
S. mutans, SAI/II antigen or BSA were coated on ELISA
plates (Nunc) at a concentration of 1–10 µg per well in
PBS overnight at 4°C. The plates were washed three times
with PBS and blocked with 2% milk powder in PBS for 2
h at room temperature. The scFvs were tested either at a
concentration of 1 µg per well or 100 µl per well of over-
night-induced culture. Recombinant antibodies contain-
ing the MYC tag were detected with the murine 9E10
monoclonal antibody (ATCC CRL1729). Antibodies con-
taining a His6 tag were detected using the murine anti-
Penta-HIS antibody (Qiagen). The murine antibodies
were detected with a goat-anti-mouse (Fc-specific) perox-
idase-labeled antibody. The assays were developed with
3,3',5,5'-tetramethylbenzidine (TMB) (Sigma). Reactions
were stopped by the addition of H2SO4 after 20 min and
readings taken at OD450 nm. Between every incubation
step, the plates were washed three times with PBS contain-
ing 0.05% Tween 20 and three times with PBS.
Inhibition ELISA was carried out by binding of chimeric
scFv to SAI/II and replacement with an excess of mAb
Guy13. Bound scFv were detected as described above
using the murine 9E10 monoclonal antibody detecting
the MYC-tag.
Agglutination of S. mutans
Cultured S. mutans was divided into 20-µl aliquots and
incubated with serial dilutions of bacterially expressed
recombinant antibodies dia mGuy13 and diaD12, respec-
tively for 2 d at 4°C or 1 h at 37°C on Lab-Tek II chamber
slides (Nalge Nunc International). As negative control an
unrelated human diabody was used. Excess medium was
discarded and the cells were air-dried. The bacteria were
counterstained with Gram solution (Diagnostica Merck).
The slides were mounted with Immunofluor medium
(ICN Biomedicals Inc) and photographed with a Zeiss
Axioskob microscope.
Authors contributions
MBK generated the diabody formats and performed all in
vitro  assays. MH did the upscaled expression of the
antibodies. HS assisted in the analysis of data. JKCM
assisted in the analysis and interpretation of the data espe-
cially in respect to the data obtained with the murine mAb
Guy13. SB assisted in the interpretation of the data. RF
assisted in the conception and revision of the project. RF*
generated the human phage display libraries, developed
the concept and supervised the project
Acknowledgement
The authors would like to thank Dr. Neil Emans for the support in gener-
ating the images of the S. mutans agglutination. For the helpful discussion 
and revision of the manuscript we thank Dr. Richard Twyman.
References
1. Balakrishnan M, Simmonds RS, Tagg JR: Dental caries is a prevent-
able infectious disease. Aust Dent J 2000, 45:235-245.
2. Hajishengallis G, Michalek SM: Current status of a mucosal vac-
cine against dental caries. Oral Microbiol Immunol 1999, 14:1-20.
3. Russell MW, Lehner T: Characterisation of antigens extracted
from cells and culture fluids of Streptococcus mutans sero-
type c. Arch Oral Biol 1978, 23:7-15.
4. Smith R, Lehner T: Characterisation of monoclonal antibodies
to common protein epitopes on the cell surface of Strepto-
coccus mutans and Streptococcus sobrinus.  Oral Microbiol
Immunol 1989, 4:153-158.
5. Lehner T, Caldwell J, Smith R: Local passive immunization by
monoclonal antibodies against streptococcal antigen I/II in
the prevention of dental caries. Infect Immun 1985, 50:796-799.
6. Ma JK, Hunjan M, Smith R, Lehner T: Specificity of monoclonal
antibodies in local passive immunization against Streptococ-
cus mutans. Clin Exp Immunol 1989, 77:331-337.
7. Ma JK, Hunjan M, Smith R, Kelly C, Lehner T: An investigation into
the mechanism of protection by local passive immunization
with monoclonal antibodies against Streptococcus mutans.
Infect Immun 1990, 58:3407-3414.
8. Saleh MN, LoBuglio AF, Wheeler RH, Rogers KJ, Haynes A, Lee JY,
Khazaeli MB: A phase II trial of murine monoclonal antibody
17-1A and interferon-gamma: clinical and immunological
data. Cancer Immunol Immunother 1990, 32:185-190.
9. Mountain A, Adair JR: Engineering antibodies for therapy. Bio-
technol Genet Eng Rev 1992, 10:1-142.
10. Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM:
Humanization of a mouse monoclonal antibody by CDR-
grafting: the importance of framework residues on loop
conformation. Protein Eng 1991, 4:773-783.
11. Beiboer SH, Reurs A, Roovers RC, Arends JW, Whitelegg NR, Rees
AR, Hoogenboom HR: Guided selection of a pan carcinoma
specific antibody reveals similar binding characteristics yet
structural divergence between the original murine antibody
and its human equivalent. J Mol Biol 2000, 296:833-849.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Biotechnology 2005, 5:4 http://www.biomedcentral.com/1472-6750/5/4
Page 12 of 12
(page number not for citation purposes)
12. Kortt AA, Dolezal O, Power BE, Hudson PJ: Dimeric and trimeric
antibodies: high avidity scFvs for cancer targeting. Biomol Eng
2001, 18:95-108.
13. Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, Hein
MB, Lehner T: Characterization of a recombinant plant mon-
oclonal secretory antibody and preventive immunotherapy
in humans. Nat Med 1998, 4:601-606.
14. Bleiweis AS, Lee SF, Brady LJ, Progulske-Fox A, Crowley PJ: Cloning
and inactivation of the gene responsible for a major surface
antigen on Streptococcus mutans.  Arch Oral Biol 1990,
35(Suppl):15S-23S.
15. Amersdorfer P, Marks JD: Phage libraries for generation of anti-
botulinum scFv antibodies. Methods Mol Biol 2000, 145:219-240.
16. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P,
Winter G: Multi-subunit proteins on the surface of filamen-
tous phage: methodologies for displaying antibody (Fab)
heavy and light chains. Nucleic Acids Res 1991, 19:4133-4137.
17. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD,
Winter G: Bypassing immunization. Human antibodies from
V-gene libraries displayed on phage.  J Mol Biol 1991,
222:581-597.
18. Holliger P, Prospero T, Winter G: Diabodies: small bivalent and
bispecific antibody fragments. Proceedings Of The National Acad-
emy Of Sciences Of The United States Of America 1993, 90:6444-6448.
19. Breitling F, Duebel S, Seehaus T, Klewinghaus I, Little M: A surface
expression vector for antibody screening.  Gene 1991,
104:147-153.
20. Barth S, Huhn M, Matthey B, Klimka A, Galinski EA, Engert A: Com-
patible-solute-supported periplasmic expression of func-
tional recombinant proteins under stress conditions.  Appl
Environ Microbiol 2000, 66:1572-1579.
21. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P,
Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, Pros-
pero TD, Hoogenboom HR, Nissim A, Cox JPL, Harrison JL, Zaccolo
M, Gherardi E, Winter G: Isolation of high affinity human anti-
bodies directly from large synthetic repertoires. EMBO J 1994,
13:3245-3260 [http://www.mrc-cpe.cam.ac.uk].